News for Semper Paratus Acquisition Corp Stock (TVGN)

Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

GlobeNewsWire • 08/14/24

Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

GlobeNewsWire • 08/09/24

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

GlobeNewsWire • 07/11/24

Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

GlobeNewsWire • 07/10/24

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

GlobeNewsWire • 07/08/24

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

GlobeNewsWire • 06/26/24

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

GlobeNewsWire • 06/25/24

Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

GlobeNewsWire • 06/18/24

Tevogen Bio Set to Join Russell 3000® Index

GlobeNewsWire • 06/12/24

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

GlobeNewsWire • 06/11/24

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

GlobeNewsWire • 06/07/24

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

GlobeNewsWire • 06/06/24

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

GlobeNewsWire • 06/06/24

Tevogen Bio Reports First Quarter 2024 Financial Results

GlobeNewsWire • 05/29/24

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

GlobeNewsWire • 05/16/24

Why Is Tevogen Bio (TVGN) Stock Up 54% Today?

InvestorPlace • 05/13/24

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

GlobeNewsWire • 05/10/24

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

GlobeNewsWire • 05/01/24

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

GlobeNewsWire • 04/26/24

Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

GlobeNewsWire • 04/11/24

Why Is Tevogen Bio (TVGN) Stock Up 46% Today?

InvestorPlace • 04/04/24

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

GlobeNewsWire • 04/03/24

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

GlobeNewsWire • 03/28/24

Tevogen Bio Announces Series A-1 Preferred Stock Investment

GlobeNewsWire • 03/27/24

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Business Wire • 03/20/24